Dhanuka Agritech Ltd

- The transcript does not explicitly mention the current or expected order book or pending orders for Dhanuka Agritech Limited. - However, it is indicated that the company expects to generate revenue from Bayer-acquired products, with full transition to Dhanuka's books by FY '27. - For FY '26, revenue from these products is expected in the range of INR 60-70 crores. - The company plans around 8 new product launches over the next 2 years to support growth. - Domestic formulation business is growing, driven largely by specialty products, with volume growth expected around 15% excluding Bayer molecules. - Channel inventory for Dhanuka is minimal, suggesting efficient inventory management and steady order flow. - No explicit mention of backlog or pending orders was made in the call.

- The company raised short-term borrowings of INR 50 crores in December for an acquisition. - This loan is expected to be repaid before December 2025. - Apart from this, the company has utilized some limits temporarily around the time of a buyback in September. - No mention of any new or future fundraising through equity was made. - Any additional clarity on royalties and financial impacts related to acquisitions is expected by end of February. - Overall, no explicit announcement of current/future large debt or equity fundraising beyond these short-term arrangements.

- No fresh CAPEX planned for Dahej plant currently due to low commercial viability of new products. - Focus on product development in R&D for new products over the next 2-3 years. - Intend to launch around 8 new products over the next 2 years, including rice herbicide and fungicide for grapes and horticultural crops in FY '26. - One molecule manufacturing shift planned to India, expected to take around 1.5 to 2 years for regulatory approvals; another product manufacturing will remain outsourced. - No fresh CAPEX at Dahej justified currently; efforts are on product development without major investments. - For international business, building a specialist team and adding positions to increase capabilities. - Acquisition of Bayer products involved capitalizing INR 160 crores in Q4; no additional CAPEX mentioned specifically for this acquisition.

- FY '26 top line growth expected around 15% excluding Bayer molecules; additional revenue from Bayer products will add to this (Page 17). - Volume growth for FY '26 is expected to be largely in line with top line growth, i.e., around 15% (Page 17). - Bayer product revenues projected to grow at 15% year-on-year for the first 5 years starting FY '27 (Page 9). - Specialty products and new product launches expected to drive volume growth, while generic products show no significant value growth but slight volume increase (Page 12, 16). - New registrations and marketing efforts are planned to revive and grow acquired Bayer products by 10-15% CAGR in subsequent years (Page 14). - Launch of about 8 new products in the next 2 years targeting crops like rice, grapes, and horticulture is planned (Page 8). - Continued focus on domestic market growth with limited growth from exports (Page 17).

- Top-line growth for FY '26 is expected around 15%, excluding revenue from Bayer molecules, which will add incremental growth. - Volume growth for FY '26 is anticipated to be largely in line with overall top-line growth (~15%), indicating volume-driven growth. - Revenue contribution from Bayer products will transition gradually in FY '26, with full revenue recognition expected by FY '27; 15% year-on-year growth expected in Bayer product revenues for first 5 years starting FY '27. - EBITDA margins for acquired Bayer products expected to align with existing company margins. - Interest cost has increased due to INR 50 crore loan for acquisition repayment by December 2025; however, the base cost remains nominal. - Margin improvement is expected to be challenging beyond current best levels (38%-39% gross margin), with focus on sustaining margins despite market and pricing challenges. - Profitability improvements anticipated as royalty income from Bayer acquisitions begins in FY '26, with clearer details expected by end of February 2025.